Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

Randomized trials have shown marked reductions in low‐density lipoprotein cholesterol (LDL‐C), a risk factor for cardiovascular disease (CVD), when evolocumab is administered. We hypothesized that evolocumab added to standard of care (SOC) vs SOC alone is cost‐effective in the treatment of patients...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cardiol
Auteurs principaux: Gandra, Shravanthi R., Villa, Guillermo, Fonarow, Gregg C., Lothgren, Mickael, Lindgren, Peter, Somaratne, Ransi, van Hout, Ben
Format: Artigo
Langue:Inglês
Publié: Wiley Periodicals, Inc. 2016
Sujets:
Quality and Outcomes
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5074319/
https://ncbi.nlm.nih.gov/pubmed/27092712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22535
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires